Shanghai Biomed-Union Biotechnology

Shanghai Biomed-Union Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies targeting the complement system and other immune-mediated pathways. The company's primary focus is on addressing unmet medical needs in hematology, nephrology, neurology, and ophthalmology. Its lead candidate, BMU-001, is a long-acting C5 inhibitor designed for the treatment of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases. Biomed-Union leverages its proprietary technology platforms to develop a diverse pipeline of monoclonal and bispecific antibodies aimed at providing more effective and convenient treatment options for patients with rare and chronic inflammatory conditions.